In addition, we consider strategic collaborations and partnerships with healthcare providers. The introduction of novel prognostic and drug response strategies into clinical oncology will lead to personalized treatment decisions for the majority of novel cancer drugs as well as for common chemotherapy modalities.

As the result, cancer patients will benefit from better and more selective therapies, fewer side effects, and longer survival. Healthcare providers will also benefit from significantly reduced treatment costs.